Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Amgen Discounting Aranesp After Medicare Reimbursement Cut

  • News

Executive Summary

Amgen is discounting Aranesp (darbepoetin alfa) to hospital customers as a result of cuts in Medicare reimbursement, the company said during a Jan. 23 earnings call

You may also be interested in...



J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes

Johnson & Johnson is taking steps to competitively position Procrit ahead of the changes to Medicare Part B reimbursement in 2005, Biopharmaceuticals Group Chairman Joe Scodari told investors July 13

J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes

Johnson & Johnson is taking steps to competitively position Procrit ahead of the changes to Medicare Part B reimbursement in 2005, Biopharmaceuticals Group Chairman Joe Scodari told investors July 13

J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount

Johnson & Johnson will not be matching Amgen's latest discounts in the EPO market, J&J CFO Robert Darretta indicated during an April 13 investor call

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

See All
UsernamePublicRestriction

Register

PS041143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By